Ivan Baz-Martinez

Association between influenza vaccination and severe outcomes in adults aged ≥ 65 years hospitalized with laboratory-confirmed influenza: a retrospective cohort study, I-MOVE hospital network, Europe, 2015/16-2024/25.

Journal: Expert review of vaccines

Published: August 27, 2026

Adapted XBB.1.5 vaccine effectiveness against severe COVID-19 outcomes among immunocompromised persons in 2023-24 in six European countries: a VEBIS-EHR network study.

Journal: Expert review of vaccines

Published: July 27, 2026

COVID-19 Vaccine Effectiveness Among Older Adults.

Journal: JAMA network open

Published: June 15, 2026

Vaccine effectiveness against medically attended, laboratory-confirmed influenza in the I-MOVE primary care network in Europe, VEBIS project, 2024/25.

Journal: Expert review of vaccines

Published: March 12, 2026

Impact of diagnostic delay in COVID-19 index cases on SARS-CoV-2 transmission to household contacts.

Journal: Medicina clinica

Published: February 02, 2026

Identification of the causal odds ratio in test-negative-design studies of COVID-19 vaccine effectiveness.

Journal: International journal of epidemiology

Published: January 12, 2026

Impact of Smoking on Household SARS-CoV-2 Transmission.

Journal: Healthcare (Basel, Switzerland)

Published: December 31, 2025

Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: November 14, 2025

Mask wearing by COVID-19 index cases reduces SARS-CoV-2 transmission to household contacts.

Journal: Epidemiology and infection

Published: October 06, 2025

Nirsevimab immunization effectiveness against respiratory syncytial virus hospitalization in newborns: two season of use in Navarre, Spain

Journal: Anales del sistema sanitario de Navarra

Published: August 29, 2025

Modelling approaches for estimating vaccine effectiveness of consecutive SARS-CoV-2 variant sublineages in the absence of study-specific genetic sequencing data, VEBIS hospital network, Europe, 2023/24.

Journal: PloS one

Published: August 29, 2025

Prevalence of influenza and other respiratory viral infections in deceased persons: a population-based observational study over four influenza seasons.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: August 07, 2025

Association between influenza vaccination and severe outcomes in adults aged ≥ 65 years hospitalized with laboratory-confirmed influenza: a retrospective cohort study, I-MOVE hospital network, Europe, 2015/16-2024/25.

Association between influenza vaccination and severe outcomes in adults aged ≥ 65 years hospitalized with laboratory-confirmed influenza: a retrospective cohort study, I-MOVE hospital network, Europe, 2015/16-2024/25.

Adapted XBB.1.5 vaccine effectiveness against severe COVID-19 outcomes among immunocompromised persons in 2023-24 in six European countries: a VEBIS-EHR network study.

Adapted XBB.1.5 vaccine effectiveness against severe COVID-19 outcomes among immunocompromised persons in 2023-24 in six European countries: a VEBIS-EHR network study.

COVID-19 Vaccine Effectiveness Among Older Adults.

COVID-19 Vaccine Effectiveness Among Older Adults.

Vaccine effectiveness against medically attended, laboratory-confirmed influenza in the I-MOVE primary care network in Europe, VEBIS project, 2024/25.

Vaccine effectiveness against medically attended, laboratory-confirmed influenza in the I-MOVE primary care network in Europe, VEBIS project, 2024/25.

Impact of diagnostic delay in COVID-19 index cases on SARS-CoV-2 transmission to household contacts.

Impact of diagnostic delay in COVID-19 index cases on SARS-CoV-2 transmission to household contacts.

Identification of the causal odds ratio in test-negative-design studies of COVID-19 vaccine effectiveness.

Identification of the causal odds ratio in test-negative-design studies of COVID-19 vaccine effectiveness.

Impact of Smoking on Household SARS-CoV-2 Transmission.

Impact of Smoking on Household SARS-CoV-2 Transmission.

Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.

Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.

Mask wearing by COVID-19 index cases reduces SARS-CoV-2 transmission to household contacts.

Mask wearing by COVID-19 index cases reduces SARS-CoV-2 transmission to household contacts.

Nirsevimab immunization effectiveness against respiratory syncytial virus hospitalization in newborns: two season of use in Navarre, Spain

Nirsevimab immunization effectiveness against respiratory syncytial virus hospitalization in newborns: two season of use in Navarre, Spain

Modelling approaches for estimating vaccine effectiveness of consecutive SARS-CoV-2 variant sublineages in the absence of study-specific genetic sequencing data, VEBIS hospital network, Europe, 2023/24.

Modelling approaches for estimating vaccine effectiveness of consecutive SARS-CoV-2 variant sublineages in the absence of study-specific genetic sequencing data, VEBIS hospital network, Europe, 2023/24.

Prevalence of influenza and other respiratory viral infections in deceased persons: a population-based observational study over four influenza seasons.

Prevalence of influenza and other respiratory viral infections in deceased persons: a population-based observational study over four influenza seasons.

Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.

Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.